510(k) K260235 ยท PZM Next Generation Sequencing Based Tumor Profiling Test
CellDx-Tissue
| Applicant | Datar Cancer Genetics Private Limited, Nasik, IN |
| Decision | Substantially Equivalent, May 12, 2026 |
| Received | Jan 26, 2026 |
| Type | Traditional |
| FDA record | Open on fda.gov |
Recalls that name K260235
No recall in the FDA data names this 510(k).
Links come from the 510(k) numbers listed on each FDA recall record. We don't infer predicate chains.